FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000981395> ?p ?o ?g. }

• W2000981395 endingPage "442" @default.
• W2000981395 startingPage "438" @default.
• W2000981395 abstract "To compare the rates of overall survival (OS), disease-free survival (DFS) and toxicity in different techniques of postoperative radiotherapy for stage IA endometrioid adenocarcionoma of endometrium, histological grades 1and 2. A historical comparison between treatment regimens was performed, and 133 women with a minimum follow-up of 5 years were included. Teletherapy (TELE group), with 22 patients treated from 1988 to 1996, with a 10 MV linear accelerator, average dose 46.2 Gy. Low dose rate brachytherapy (LDRB group) was performed between 1992 and 1995, in 19 women, with an insertion of Cesium 137, at a 60 Gy dose. Fourteen women operated between 1990 and 1996 did not receive radiotherapy (NO RT group). High dose rate brachytherapy was performed in 78 patients (HDRB group), from 1996 to 2004, in five weekly 7 Gy insertions, prescribed at 0.5 cm from the vaginal cylinder. The 5-year disease-free survival was 94.6% for the HDRB group, 94.1% for the LDRB group, 100% for the TELE group and NO RT groups (p = 0.681). The 5-year overall survival was 86.6% for the HDRB group, 89.5% for the LDRB group and 90% for the TELE group and NO RT groups (p = 0.962). Grades 3-5 late toxicity was 5.3% in LDRB group and 27.3% for the TELE group (p < 0.001). Patients submitted to adjuvant teletherapy showed very high toxicity, which contraindicates that treatment for those patients. There may be a role for adjuvant HDRB, but randomized controlled trials are still needed to evaluate its benefit. Comparar as taxas de sobrevida global (SG), sobrevida livre de doença (DFS) e de toxicidade em diferentes técnicas de radioterapia pós-operatória para adenocarcionoma endometrioide do endométrio estádio IA, graus histológicos 1 e 2. Realizou-se uma comparação histórica entre regimes de tratamento, incluindo 133 mulheres com seguimento mínimo de cinco anos. Teleterapia (grupo TELE), com 22 pacientes, de 1988 a 1996, tratadas com acelerador linear 10 MV, dose média de 46,2 Gy. Braquiterapia de baixa taxa de dose (grupo LDRB), realizada entre 1992 e 1995, em 19 mulheres, com uma inserção de Césio 137, dose de 60 Gy. Quatorze mulheres operadas entre 1990 e 1996 não receberam radioterapia (grupo NO RT). Braquiterapia de alta taxa de dose foi realizada em 78 pacientes (grupo BATD), 1996–2004, cinco inserções semanais de 7 Gy, a 0,5 cm do cilindro vaginal. A DFS em cinco anos foi de 94,6% para o grupo BATD, 94,1% para o grupo LDRB, 100% para os grupos TELE e RT (p = 0,681). A sobrevida global em cinco anos foi de 86,6% para o grupo BATD, 89,5% para o grupo LDRB e 90% para os grupos TELE e NO RT (p = 0,962). A toxicidade tardia graus 3–5 foi de 5,3% no grupo LDRB e 27,3% para o grupo TELE (p < 0,001). Pacientes submetidos à teleterapia adjuvante apresentaram toxicidade muito elevada, o que contraindica o tratamento para essas pacientes. Pode haver um papel para a BATD adjuvante, mas estudos controlados randomizados são necessários para avaliar seu benefício." @default.
• W2000981395 created "2016-06-24" @default.
• W2000981395 creator A5006916352 @default.
• W2000981395 creator A5030531320 @default.
• W2000981395 creator A5045914337 @default.
• W2000981395 creator A5046486555 @default.
• W2000981395 creator A5074568644 @default.
• W2000981395 creator A5080845089 @default.
• W2000981395 date "2011-07-01" @default.
• W2000981395 modified "2023-10-11" @default.
• W2000981395 title "Adjuvant radiotherapy in early stage endometrial cancer" @default.
• W2000981395 cites W1982472596 @default.
• W2000981395 cites W1983923224 @default.
• W2000981395 cites W1992321249 @default.
• W2000981395 cites W2024578237 @default.
• W2000981395 cites W2031222466 @default.
• W2000981395 cites W2043945205 @default.
• W2000981395 cites W2044590088 @default.
• W2000981395 cites W2063700258 @default.
• W2000981395 cites W2064419994 @default.
• W2000981395 cites W2085294894 @default.
• W2000981395 cites W2085768767 @default.
• W2000981395 cites W2090746250 @default.
• W2000981395 cites W2097409147 @default.
• W2000981395 cites W2101839617 @default.
• W2000981395 cites W2147101451 @default.
• W2000981395 cites W4255462147 @default.
• W2000981395 doi "https://doi.org/10.1590/s0104-42302011000400019" @default.
• W2000981395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21876927" @default.
• W2000981395 hasPublicationYear "2011" @default.
• W2000981395 type Work @default.
• W2000981395 sameAs 2000981395 @default.
• W2000981395 citedByCount "4" @default.
• W2000981395 countsByYear W20009813952012 @default.
• W2000981395 countsByYear W20009813952014 @default.
• W2000981395 countsByYear W20009813952019 @default.
• W2000981395 crossrefType "journal-article" @default.
• W2000981395 hasAuthorship W2000981395A5006916352 @default.
• W2000981395 hasAuthorship W2000981395A5030531320 @default.
• W2000981395 hasAuthorship W2000981395A5045914337 @default.
• W2000981395 hasAuthorship W2000981395A5046486555 @default.
• W2000981395 hasAuthorship W2000981395A5074568644 @default.
• W2000981395 hasAuthorship W2000981395A5080845089 @default.
• W2000981395 hasBestOaLocation W20009813951 @default.
• W2000981395 hasConcept C121608353 @default.
• W2000981395 hasConcept C126322002 @default.
• W2000981395 hasConcept C126894567 @default.
• W2000981395 hasConcept C141071460 @default.
• W2000981395 hasConcept C146357865 @default.
• W2000981395 hasConcept C151730666 @default.
• W2000981395 hasConcept C168563851 @default.
• W2000981395 hasConcept C2776283816 @default.
• W2000981395 hasConcept C2777088508 @default.
• W2000981395 hasConcept C2777416452 @default.
• W2000981395 hasConcept C2777785397 @default.
• W2000981395 hasConcept C2777863537 @default.
• W2000981395 hasConcept C29730261 @default.
• W2000981395 hasConcept C2989005 @default.
• W2000981395 hasConcept C509974204 @default.
• W2000981395 hasConcept C71924100 @default.
• W2000981395 hasConcept C86803240 @default.
• W2000981395 hasConcept C90924648 @default.
• W2000981395 hasConceptScore W2000981395C121608353 @default.
• W2000981395 hasConceptScore W2000981395C126322002 @default.
• W2000981395 hasConceptScore W2000981395C126894567 @default.
• W2000981395 hasConceptScore W2000981395C141071460 @default.
• W2000981395 hasConceptScore W2000981395C146357865 @default.
• W2000981395 hasConceptScore W2000981395C151730666 @default.
• W2000981395 hasConceptScore W2000981395C168563851 @default.
• W2000981395 hasConceptScore W2000981395C2776283816 @default.
• W2000981395 hasConceptScore W2000981395C2777088508 @default.
• W2000981395 hasConceptScore W2000981395C2777416452 @default.
• W2000981395 hasConceptScore W2000981395C2777785397 @default.
• W2000981395 hasConceptScore W2000981395C2777863537 @default.
• W2000981395 hasConceptScore W2000981395C29730261 @default.
• W2000981395 hasConceptScore W2000981395C2989005 @default.
• W2000981395 hasConceptScore W2000981395C509974204 @default.
• W2000981395 hasConceptScore W2000981395C71924100 @default.
• W2000981395 hasConceptScore W2000981395C86803240 @default.
• W2000981395 hasConceptScore W2000981395C90924648 @default.
• W2000981395 hasIssue "4" @default.
• W2000981395 hasLocation W20009813951 @default.
• W2000981395 hasLocation W20009813952 @default.
• W2000981395 hasLocation W20009813953 @default.
• W2000981395 hasOpenAccess W2000981395 @default.
• W2000981395 hasPrimaryLocation W20009813951 @default.
• W2000981395 hasRelatedWork W2016426829 @default.
• W2000981395 hasRelatedWork W2057864422 @default.
• W2000981395 hasRelatedWork W2081888286 @default.
• W2000981395 hasRelatedWork W2348402540 @default.
• W2000981395 hasRelatedWork W2389281101 @default.
• W2000981395 hasRelatedWork W2407572472 @default.
• W2000981395 hasRelatedWork W2411709837 @default.
• W2000981395 hasRelatedWork W2413279076 @default.
• W2000981395 hasRelatedWork W3107042173 @default.
• W2000981395 hasRelatedWork W4240628612 @default.
• W2000981395 hasVolume "57" @default.
• W2000981395 isParatext "false" @default.

• next